Kazia Therapeutics Limited — Form 20-F Summary
Period: The filing is an annual report for the fiscal year ended June 30, 2020, filed October 22, 2020, and reports under IFRS in Australian dollars (A$). This differs from the request metadata of “2019 Q4.” Kazia is a pre-revenue, oncology-focused biotechnology company; its ADSs trade on Nasdaq as KZIA.
Financial performance and position
| Metric | FY2020 | FY2019 |
|---|---|---|
| Product revenue | A$0 | A$0 |
| Revenue and other income | A$1.061m | A$1.565m |
| Research and development expense | A$9.494m | A$6.475m |
| General and administrative expense | A$3.690m | A$3.785m |
| Loss before income tax | A$12.765m | A$10.568m |
| Income tax benefit | A$0.298m | A$0.298m |
| Net loss | A$12.467m | A$10.270m |
| Basic and diluted loss per share | A$0.1707 | A$0.1786 |
| Net cash used in operating activities | A$8.810m | A$6.714m |
| Cash and cash equivalents at year end | A$8.764m | A$5.434m |
- Total assets were A$23.063m, total liabilities A$8.938m, and net assets A$14.125m at June 30, 2020. Current assets were A$10.653m against current liabilities of A$5.067m.
- Kazia reported no borrowings or credit facility. A$464,000 of Triaxial convertible notes is classified as equity, not debt, and may convert into 1,856,000 ordinary shares if specified milestones occur.
- Cash and cash equivalents included A$7.5m in short-term deposits, with a weighted average interest rate of 0.95%. The company reported no dividends.
Material changes and financing
- R&D expense rose 47% year over year, chiefly reflecting development of paxalisib, while G&A expense decreased 3%. The net loss increased 21%, reflecting higher R&D spending and a lower Australian R&D tax rebate.
- Operating cash use increased from A$6.714m to A$8.810m. Financing provided A$12.139m in FY2020, primarily through share placements and a share purchase plan. Ordinary shares outstanding grew from 62.2m to 94.6m during the year.
- After year-end, Kazia raised approximately A$24m net in an October 2020 fully underwritten entitlement offer. The filing says the proceeds would support the GBM AGILE study and working capital. This subsequent financing is not included in FY2020 year-end cash.
Business, outlook, and risks
- Paxalisib: The lead candidate was in five clinical trials, including a Kazia-sponsored Phase II study in glioblastoma (GBM). Interim data reported median progression-free survival of 8.5 months and median overall survival of 17.7 months in the newly diagnosed, MGMT-unmethylated GBM study; final data was expected in late 2020 or early 2021. These are interim results, and the filing cautions that clinical results may not predict later outcomes.
- Cantrixil: The Phase I ovarian cancer trial reported an interim 19% overall response rate among 16 evaluable patients and median progression-free survival of 5.5 months. Final data was expected by the end of calendar 2020.
- Management expected FY2021 updates on both candidates and interim paxalisib data from investigator-led studies, and expected recruitment to paxalisib’s GBM AGILE pivotal study to commence in the second half of calendar 2020. Kazia discontinued its own planned Phase III GBM study in favor of GBM AGILE.
- Management estimated that cash on hand at June 30, 2020, together with readily realizable assets, would fund planned R&D activity until approximately the first quarter of calendar 2022. This estimate preceded the subsequent October financing. The company expects continued losses and cash consumption and depends on future capital, partnerships, licensing, or grants; inability to secure funding could require reduced or ceased operations.
- Key risks include clinical failure or unexpected toxicity, regulatory and trial delays, competition, reliance on external trial and manufacturing partners, dilution from future equity raises, and possible reductions in Australian R&D rebates. COVID-19 added financing-market uncertainty; management said key trials were recruited before restrictions and GBM AGILE remained on track at the time of reporting.
- An Austrian IP dispute with APOtrend remains unresolved. Kazia may pursue claims regarding two products, while APOtrend could seek damages relating to a third; no claim had been made by either party as of the report. A A$409,098 court guarantee supports potential claims, and the related receivable remains fully impaired.
Important facts for investors to verify
- Subsequent audited or trial disclosures for the final paxalisib GBM and Cantrixil results, and whether GBM AGILE enrollment and milestones proceeded on schedule.
- Actual cash runway after the October 2020 entitlement offer, study costs, and any additional financing or dilution requirements.
- Clinical significance and durability of the reported interim efficacy results, including study populations, follow-up, and comparison limitations.
- Current status and potential financial exposure of the APOtrend proceedings and the contingent consideration obligations.
- Whether Australian R&D rebate eligibility and amounts change as more trial spending occurs outside Australia.